Welcome to our dedicated page for Veon SEC filings (Ticker: VEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to track how currency swings, spectrum fees, and 200 million subscribers shape VEON’s results? The company’s cross-border disclosures span hundreds of pages and multiple form types, making it hard to locate specifics like country-level ARPU or debt covenants. That complexity explains why searches for “VEON SEC filings explained simply” and “VEON insider trading Form 4 transactions” keep rising.
Stock Titan turns that search into clarity. Our AI parses every submission—from the Form 20-F that acts as VEON’s annual report to each 6-K interim update—then maps key numbers to plain language. Need the latest VEON quarterly earnings report 10-Q filing equivalent? We tag the 6-K for you and surface revenue, subscriber adds, and FX impacts in seconds. Curious about governance? One click shows the VEON proxy statement executive compensation section, while real-time alerts flag VEON Form 4 insider transactions real-time so you can monitor executive buys and sells. Our coverage also includes every VEON 8-K material events explained notice, ensuring you never miss a debt refinancing, spectrum auction result, or divestiture announcement.
Behind each document you’ll find an AI-generated synopsis, risk heat-map, and side-by-side metrics—ideal for analysts comparing segments like Beeline Russia versus Jazz Pakistan. Use the platform to:
- Compare subscriber growth with historical trends via VEON earnings report filing analysis
- Watch VEON executive stock transactions Form 4 for sentiment signals
- Download the VEON annual report 10-K simplified narrative and key tables, or dive deeper by understanding VEON SEC documents with AI
Schedule 13D/A Amendment No. 4 filed by OrbiMed-affiliated entities discloses a material change in their ownership of Ikena Oncology, Inc. (NASDAQ: IKNA) common stock.
On 14 June 2025 OrbiMed Private Investments VI, LP (OPI VI), OrbiMed Genesis Master Fund, L.P. (Genesis) and Worldwide Healthcare Trust PLC (WWH) notified the issuer that they were raising the beneficial-ownership cap on their Non-Voting Shares from 9.99 % to 19.99 %. Because of this action, 6,042,193 Non-Voting Shares will automatically convert into voting common shares 61 days after the notice date. The conversion lifts the total number of shares the “Reporting Persons” may be deemed to own by more than 1 %, triggering this amendment.
Post-conversion beneficial ownership (based on 47,931,718 total shares assumed outstanding):
- OrbiMed Advisors LLC – 8,008,913 shares (16.71 % of class) with shared voting & dispositive power.
- OrbiMed Capital GP VI LLC (general partner of OPI VI) – 7,768,790 shares (16.21 %).
- OrbiMed Capital LLC (investment adviser to WWH) – 1,572,638 shares (3.28 %) held with sole voting & dispositive power.
- OrbiMed Genesis GP LLC – 240,123 shares (0.50 %).
The filing reiterates historical agreements connected to OrbiMed’s 2023‐backed merger between IKNA and Pionyr Immunotherapeutics, including Investors’ Rights, Support and Contingent Value Rights (CVR) agreements that grant demand, piggy-back and Form S-3 registration rights, lock-up provisions, and a 50 % share in net proceeds from any sale of Pionyr’s legacy assets.
No immediate plans to alter IKNA’s strategy, board or capital structure are declared. OrbiMed states it may acquire or dispose of shares opportunistically, depending on market conditions.
FAQ
What is the current stock price of Veon (VEON)?
What is the market cap of Veon (VEON)?
What is the core business of VEON Ltd?
In which countries does VEON operate?
Which brands are associated with VEON Ltd?
How does VEON generate its revenue?
What are the key competitive advantages of VEON Ltd?
How does VEON enhance its service quality?
How does VEON manage regulatory and market challenges?
What makes VEON Ltd significant in the digital services market?
